Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Purple Biotech Q2 EPS $(0.09) Beats $(0.12) Estimate

Author: Benzinga Newsdesk | August 16, 2024 08:14am

Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12) by 25 percent. This is a 64 percent increase over losses of $(0.25) per share from the same period last year.

Posted In: PPBT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist